Cipla rises 3% as USFDA clears InvaGen plant
CIPLA Limited (CIPLA) rose as much as 3% to a day high of ₹1,435 on November 18, after the US Food and Drug Administration (USFDA) gave a clean chit to its InvaGen plant in New York. The stock traded at ₹1,432.80 at 11:37 AM, up 3.23% from the previous close of ₹1,388. Cipla disclosed the update late on November 17. The USFDA classified InvaGen’s Hauppauge facility on Long Island as No Action Indicated (NAI), the best possible outcome of an inspection. The inspection took place from October 19 to 22, and the report formally closes an earlier inspection at the site. InvaGen is Cipla’s wholly owned US subsidiary. A clean inspection removes a regulatory overhang. With NAI status, the plant can keep supplying the US market and support new product approvals without the risk of warning letters or import restrictions. For a company with a large US business, a compliant manufacturing base is essential. The clearance does not fix the bigger US problem. North America revenue in Q2 was $172 million, up $10 million from the previous quarter but 19% lower than a year ago. A clean plant helps protect existing business, but growth depends on new product launches. Investors will want to see whether Cipla can build a US pipeline strong enough to reverse the yearly decline. Investors should watch new US product approvals and launches, North America revenue in coming quarters, other pending USFDA inspections, and India business growth. The key question is whether Cipla can turn a clean regulatory record into renewed US growth. Disclosure: I do not hold any position in Cipla Limited. This post is for informational purposes only and is not investment advice.



















